XM no presta servicios a los residentes de Estados Unidos de América.

Chip stocks, megacaps steer S&P 500, Nasdaq to record highs



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Chip stocks, megacaps steer S&P 500, Nasdaq to record highs</title></head><body>

For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.

S&P 500 notches 35th record closing high this year

Lilly up after data shows Mounjaro more efficient than Wegovy

Indexes: Dow down 0.38%, S&P up 0.21%, Nasdaq up 0.47%

Updated at 10:05 a.m. ET

By Lisa Pauline Mattackal and Ankika Biswas

July 9 (Reuters) - The S&P 500 and the Nasdaq hit record highs on Tuesday, powered by semiconductors andmegacaps, as Congress heard testimony from Federal Reserve Chair Jerome Powell, who said more "good" economic data would strengthen the case for interest-rate cuts.

AI-chip favorite Nvidia NVDA.O jumped 4%, while Applied Materials AMAT.O and Micron Technology MU.O gained 2% and 3%, respectively, steering the Philadelphia SE Semiconductor index .SOX to a record high.

The S&P 500 Information Technology Index .SPLRCT also hit an all-time high, along with megacaps including Alphabet GOOGL.O and Apple AAPL.O, while Meta Platforms META.O and Amazon.com AMZN.O rose0.9% and 0.3%, respectively.

Monday markedthe 35th instance of the S&P 500setting a fresh closing record this year, as sharp gains in AI-linked and other tech shares kept equity sentiment bright, offsetting the uncertainty around the Fed'srate-cut path.

However, the Dow Jones .DJI underperformed, with a 2% fall in Salesforce CRM.N being the biggest drag on the blue-chip index.

Meanwhile, in his Congressional testimony, Powell said that while inflation "remains above" the 2% soft-landing target, it has been improving in recent months and "more good data would strengthen" the case for rate cuts.

"It does sound like Powell is just looking for a few more months of decent inflation data in order to have the confidence to start cutting, so that could put a September rate cut in play," said Brian Jacobsen, chief economist at Annex Wealth Management.

The last set of economicprojections from the central bank's policymakers showed anexpectation of just one rate cut this year. But markets have stuck to pricing in 50 basis points of easing, seeing a nearly 72% chance for a 25 bps cut at the Fed's September meeting, according to CME's FedWatch.

Those bets were at under50% a month ago.

Crucial inflation data is also due this week, including Thursday'sconsumer price index and the producerprice index reading on Friday.

Investors also awaitthe start of the second-quarter corporate earnings season this week, with big banks due to report on Friday.

Analysts, on average, see S&P 500 companies increasing their aggregate earnings per share by 10.1% in the second quarter, up from an 8.2% increase in the first quarter, according to LSEG I/B/E/S data.

At 10:05 a.m. ET, the Dow Jones Industrial Average .DJI was down 147.89 points, or 0.38%, at 39,196.90, the S&P 500 .SPX was up 11.96 points, or 0.21%, at 5,584.81, and the Nasdaq Composite .IXIC was up 86.31 points, or 0.47%, at 18,490.05.

Among single movers, Tempus AI TEM.O jumped7.5% after multiple brokerages including J.P.Morgan and Morgan Stanley initiated coverage of the stock with bullish ratings.

Eli Lilly <LLY.N> edgedup 0.6% aftera data analysis report showed its treatment Mounjaro leads to faster and greater weight loss than Novo Nordisk's obesity drug, Wegovy.

CVS Health CVS.N and UnitedHealth Group UNH.N fell0.9% and 0.4%, respectively, after the U.S. Federal Trade Commission said a handful of pharmacy benefit managersexercized an outsized influence over prescription drug prices.

Declining issues outnumbered advancers for a 1.51-to-1 ratio on the NYSE, andfor a 1.31-to-1 ratio on the Nasdaq.

The S&P index recorded 19 new 52-week highs and ninenew lows, while the Nasdaq recorded 38 new highs and 74 new lows.



Reporting by Lisa Mattackal and Ankika Biswas in Bengaluru; Editing by Pooja Desai

</body></html>

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.